T he recent upgrade of the H1N1 flu infection to a pandemic experience has illuminated several lessons regarding public health management and monitoring in the new age of technology. The prompt and timely dissemination of information on the spread of H1N1 disease, methods for prevention and treatment, and management of resources has been effectively handled by a variety of sources. Predictably, the Internet has played a prominent role as a source for information, both good and bad, regarding the H1N1 influenza virus as it marches around the world. Many forms of communication are used in times of noncrisis and crisis, but the major ad vantages of the Internet as a resource are its accessibility and the ability of users to update information in a timely manner. For patients, however, there may be difficulty in determining which health information is reliable, and in times of public health urgency, consumers may be particularly vulnerable to the marketing and sales of unapproved, untested products. Soon after the recognition of the H1N1 flu as a public health phenomenon, Internet promotion for a variety of "therapies" appeared; this included, but was not limited to, shampoos, inhalers, sprays, dietary supplements, and a photobiotic electronic scanner. In most cases, the costs of these products were moderate, but for a few isolated promotions, the cost was in the thousands of dollars. Furthermore, purchase price is merely one measure of cost; poor judgment knows no budget. The use of untested products carries a safety risk inherent to the utilization of such products alone or in combination with medications that a patient may be taking. In addition, the delay of appropriate treatment also may be an issue.
In mid-June, the US Food and Drug Administration (FDA) published a health advisory that warned consumers of the dangers from illegal products sold on the Internet "claiming to diagnose, pre-vent, mitigate, treat or cure the 2009 H1N1 flu virus."
1 The FDA has issued at least 50 warning letters to such sites, most of which have removed the products in question. Health care professionals should be vigilant in educating patients about reliable sources for information regarding the H1N1 influenza, including the Centers for Disease Control and Prevention and FDA information sites. In the United States, influenza peak periods typically occur in late fall and winter. As these seasons approach, pharmacists should be reminded to ask patients about nontraditional medications or recent additions to medication profiles that may have been purchased to prevent or combat "flu" symptoms.
